Bora Pharmaceuticals
Bora Pharmaceuticals is a Taiwan-based global CDMO operating nine cGMP facilities across Taiwan, Canada, and the United States, providing formulation development, clinical and commercial manufacturing, and packaging of oral solid dose, sterile injectables, biologics, and ophthalmic products to pharmaceutical companies in 100+ markets.
- Company typePublic
- Founded2007
- HeadquartersTaipei City, Taiwan
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What Bora Pharmaceuticals does
Bora Pharmaceuticals is a Taiwan-headquartered, Taiwan Stock Exchange-listed (TWSE: 6472) global contract development and manufacturing organization (CDMO) founded in 2007 by Bobby Sheng. The company operates nine cGMP manufacturing facilities across Taiwan, Canada, and the United States, with capabilities spanning oral solid dose, semi-solids, liquids, nasal sprays, ophthalmic, sterile injectables (including lyophilization and pre-filled syringes), and biologics (mAbs, fusion proteins, biosimilars). Manufacturing sites are approved by USFDA, MHRA, Health Canada, ANVISA, Japan FDA, and other major regulatory bodies, enabling commercial supply to more than 100 markets.
The company delivers end-to-end CDMO services from formulation development through clinical and commercial manufacturing, analytical testing, stability storage, and packaging with serialization. Technology platforms include Modified Release, Extrusion Spheronization, Wuster Coating, and High-Potency Liquid Capsule capabilities, with the Baltimore-Camden facility adding Groninger FlexPro 50 aseptic filling with isolator technology and the Taoyuan facility providing a dedicated 6,891 m² sterile ophthalmic operation.
Bora generates revenue primarily through multi-year contract manufacturing agreements and project-based CDMO engagements with pharmaceutical and biotech customers. Its customer base includes major enterprise relationships such as GSK ($250M five-year contract for 20+ products), Celltrion, KYOWA Pharmaceutical, Tanvex, DotBio, and SunWay Biotech/Gnosis. The company employs approximately 1,900 staff globally and has executed a sustained acquisition-driven growth strategy, including the $210M Upsher-Smith acquisition (April 2024) and Emergent BioSolutions' Camden sterile facility (August 2024).
Bora Pharmaceuticals firmographics
Firmographics- Name
- Bora Pharmaceuticals
- Legal name
- Bora Pharmaceuticals Co., Ltd.
- Website
- https://boracdmo.com
- Company type
- Public
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Bora Pharmaceuticals is a Taiwan-based global CDMO operating nine cGMP facilities across Taiwan, Canada, and the United States, providing formulation development, clinical and commercial manufacturing, and packaging of oral solid dose, sterile injectables, biologics, and ophthalmic products to pharmaceutical companies in 100+ markets.
- Ownership category
- akta.pro rank
Bora Pharmaceuticals industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing (CDMO)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
- akta.pro secondary industries
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ)
Keywords
Where Bora Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Taipei City
- HQ country
- Taiwan
- HQ region
- Asia
Offices8 records
Markets served
Bora Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales
Revenue model
- Contract Development and Manufacturing (CDMO) Services: Bora generates revenue through providing contract development and manufacturing services to pharmaceutical companies. Services include formulation development, clinical and commercial cGMP manufacturing, analytical testing, and packaging of pharmaceutical products. Revenue is generated through long-term contracts with pharmaceutical companies for drug product manufacturing and development.
- Strategic Manufacturing Partnerships: Revenue from strategic partnerships such as the $250M five-year GSK global manufacturing contract and other multi-year CDMO agreements with pharmaceutical companies.
- Commercial Manufacturing Supply: Supply of manufactured drug products to pharmaceutical partners for commercial distribution in global markets
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom CDMO services with project-based pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Bora Pharmaceuticals product offering
Product offeringCore offering
Bora Pharmaceuticals is a global Contract Development and Manufacturing Organization (CDMO) that provides formulation development, clinical and commercial cGMP manufacturing, analytical testing, and packaging services for complex oral solid dose, semi-solids, liquids, nasal sprays, ophthalmic, sterile injectables, and biologic pharmaceutical products. Operating nine cGMP facilities across Taiwan, Canada, and the United States, the company serves pharmaceutical and biotech clients across more than 100 global markets.
Product overview
Bora Pharmaceuticals is a global Contract Development and Manufacturing Organization (CDMO) operating as a unified platform of pharmaceutical manufacturing services. The company offers comprehensive end-to-end capabilities spanning formulation development, analytical services, clinical and commercial cGMP manufacturing, and packaging across nine facilities in Taiwan, Canada, and the United States. The product portfolio includes Oral Solid Dose, Semi-Solids, Liquids, Nasal Spray, Ophthalmic, and Sterile Injectables manufacturing services, complemented by Biologics capabilities for large molecule development. Key technology platforms include Modified Release, Extrusion Spheronization, and Wuster Coating. Development services encompass Formulation Development, Analytical Development, Analytical Testing, and Stability Testing. Manufacturing services include Small Scale & Pilot, Scale-Up & Commercial, and Packaging & Serialization. The company serves 100+ global markets with regulatory approvals from USFDA, MHRA, Health Canada, ANVISA, and other major authorities.
Differentiator
Problem solved
Functional benefit
Brands
- Bora Biologics: Biologics CDMO services including cell line development, process development, and GMP manufacturing
- Upsher-Smith
Products and services
- Oral Solid Dose Manufacturing cGMP manufacturing of oral solid dosage forms including tablets and capsules with scalable batch sizes from clinical to commercial scale, for pharmaceutical company clients.
- Semi-Solids Manufacturing cGMP manufacturing services for semi-solid pharmaceutical formulations including creams, ointments, and gels for pharmaceutical clients.
- Liquids Manufacturing cGMP manufacturing of liquid pharmaceutical dosage forms for clinical and commercial supply for pharmaceutical clients.
- Nasal Spray Manufacturing Specialized cGMP manufacturing services for nasal spray drug delivery systems for pharmaceutical clients.
- Ophthalmic CDMO Manufacturing Services Sterile ophthalmic manufacturing including solutions, emulsions, creams, ointments, and gels at a dedicated 6,891m2 FDA-approved facility in Taoyuan City, Taiwan for pharmaceutical clients.
- Sterile Injectables Manufacturing Aseptic fill/finish services for sterile injectables including vials, pre-filled syringes, and lyophilization, featuring Groninger FlexPro 50 aseptic filling line with isolator technology, for pharmaceutical clients.
- Biologics Development and Manufacturing Large molecule CDMO services including cell line development, process development, analytical development, and GMP manufacturing for monoclonal antibodies, fusion proteins, biosimilars, and multi-specific antibodies for biotech and pharmaceutical clients.
- Formulation Development Early-stage formulation development services supporting drug product development from pre-formulation through clinical manufacturing for pharmaceutical clients.
- Analytical Development Comprehensive analytical method development and validation services for pharmaceutical products for pharmaceutical clients.
- Analytical Testing Full spectrum analytical testing services including in-process testing, release testing, and characterization for pharmaceutical clients.
- Stability Testing and Storage Stability study execution and controlled storage conditions for pharmaceutical products for pharmaceutical clients.
- Packaging and Serialization Commercial packaging services with serialization capabilities to meet global track-and-trace requirements for pharmaceutical clients.
- Small Scale and Pilot Manufacturing Clinical-scale manufacturing capabilities for early-stage drug development and validation runs for pharmaceutical clients.
- Scale-Up and Commercial Manufacturing Large-scale commercial manufacturing services to support product launch and ongoing market supply for pharmaceutical clients.
- U.S. Manufacturing U.S.-based pharmaceutical manufacturing capabilities across Minnesota and Maryland facilities for domestic and international supply for pharmaceutical clients.
- Modified Release Technologies Specialized modified release drug delivery technologies for patient-centric formulations offered to pharmaceutical clients.
- Extrusion Spheronization Controlled release pellet manufacturing technology using extrusion and spheronization processes offered to pharmaceutical clients.
- Wuster Coating Advanced coating technology for pharmaceutical pellets and tablets offered to pharmaceutical clients.
- Solvent-Based Manufacturing Solvent-based manufacturing capabilities for specialized pharmaceutical formulations offered to pharmaceutical clients.
Quantifiable outcome
- 95%+ of projects completed on time and in full
- +2 more outcomes
Companies that use Bora Pharmaceuticals
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Bora Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
Bora Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and strategic.
- GSKcore$250M five-year global manufacturing contract. Bora manufactures more than 20 commercial products for GSK at its global facilities.
- Corealis PharmacoreStrategic alliance to create seamless, end-to-end solution for oral solid dose development and manufacturing. Combines Bora's global commercial infrastructure and scale-up expertise with Corealis's early-phase development and clinical-scale manufacturing capabilities.
- DotBiostrategicBora Biologics announced strategic collaboration to accelerate key CMC development of DotBio's tri-specific antibody to treat cancer.
- Insilico MedicinestrategicPartnership to create an end-to-end AI-integrated drug development model, combining Bora's global manufacturing quality and commercialization capabilities with Insilico's AI technology.
- Gnosis by LesaffrestrategicStrategic partnership to launch MenaQ7 Metabolic featuring ANKASCIN 568-R ingredient. Combines SunWay Biotech's red yeast rice technology with Gnosis's vitamin K2 expertise.
- Tanvex BioPharmastrategicTanvex BioPharma completed acquisition of Bora Biologics, launching new era in biologics development. Bora made strategic investment into Tanvex to provide global biomanufacturing services.
- SunWay BiotechstrategicBora became major shareholder of SunWay Biotech. SunWay brings exclusive technologies and raw material formulation expertise in nutraceuticals.
- CelltrioncorePartnership to contract manufacture and commercialize a range of oral dosage form drugs across the APAC region. Products manufactured at Bora's Zhunan Site for regulatory filings in seven countries.
- KYOWA Pharmaceutical Industry Co. Ltd.corePartnership to manufacture generic product for filing in Japan. KYOWA selected Bora for manufacturing capabilities.
Scale indicators8 records
Recent moves11 records
Expansion highlights8 records
Bora Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Lonza: Swiss-listed global CDMO with leading small-molecule API and biologics capabilities. Comparable in CDMO model and customer base; Lonza is much larger and a benchmark for Bora's biologics ambitions.
- Thermo Fisher Scientific (CDMO Services): Operates a large pharmaceutical product and CDMO business via Patheon. Comparable in oral solid dose, sterile, and biologics CDMO services; much larger and more diversified than Bora.
- Catalent (Novo Holdings): Global CDMO leader offering softgel, oral dose, biologics, and sterile fill-finish across a much larger network. Directly comparable to Bora across multiple dosage forms; Bora is a smaller, more focused alternative.
- Samsung Biologics: South Korea-based biologics CDMO with very large single-site mAb capacity. Comparable as a regional Asian CDMO competitor with biologics focus, particularly relevant for Bora Biologics.
Direct peers
- Recipharm: European CDMO with strong oral solids, sterile, and biologics capabilities. Directly comparable as a multi-site CDMO serving pharma customers globally with similar dosage-form breadth.
- Aenova: European CDMO specializing in solid, semi-solid, and sterile dosage forms. Comparable in dosage-form breadth and contract manufacturing model, though focused on European markets.
- Delpharm: France-based CDMO with broad oral solid, sterile, and semi-solid manufacturing across multiple sites. Comparable multi-site European CDMO peer, primarily serving European pharma customers.
- WuXi STA (WuXi AppTec): China-based CDMO offering small-molecule API and drug product, formulation, and analytical services. Closest geographic and capability competitor to Bora in Asia, though currently affected by US BIOSECURE-related headwinds.
- Siegfried Holding: Swiss CDMO focused on API and finished drug products including oral solids and sterile. Comparable in CDMO model, complexity focus, and customer base to Bora's small-molecule business.
- Piramal Pharma Solutions: India-based CDMO offering sterile injectables, oral solids, and integration services. Comparable in cross-border M&A-driven expansion and CDMO service breadth.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Bora Pharmaceuticals social profiles
Digital presenceBora Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bora Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles10 records
Bora Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries6 records
Bora Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bora Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bora Pharmaceuticals
What does Bora Pharmaceuticals do?
Bora Pharmaceuticals is a global Contract Development and Manufacturing Organization (CDMO) that provides formulation development, clinical and commercial cGMP manufacturing, analytical testing, and packaging services for complex oral solid dose, semi-solids, liquids, nasal sprays, ophthalmic, sterile injectables, and biologic pharmaceutical products. Operating nine cGMP facilities across Taiwan, Canada, and the United States, the company serves pharmaceutical and biotech clients across more than 100 global markets.
Is Bora Pharmaceuticals a public or private company?
Bora Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Bora Pharmaceuticals founded?
Bora Pharmaceuticals was founded in 2007. It employs 501 to 1,000 people.
Where is Bora Pharmaceuticals based?
Bora Pharmaceuticals is headquartered in Taipei City, Taiwan, in the Asia region.
How does Bora Pharmaceuticals make money?
Three revenue lines are on record. Contract Development and Manufacturing (CDMO) Services are the primary driver. The others are strategic Manufacturing Partnerships and commercial Manufacturing Supply.
Who are Bora Pharmaceuticals's main competitors?
Broad incumbents on record are Lonza, Thermo Fisher Scientific (CDMO Services), Catalent (Novo Holdings) and Samsung Biologics. Direct peers are Recipharm, Aenova, Delpharm, WuXi STA (WuXi AppTec), Siegfried Holding and Piramal Pharma Solutions.
Does Bora Pharmaceuticals have an API?
No public API is recorded for Bora Pharmaceuticals.
What industry is Bora Pharmaceuticals in?
Bora Pharmaceuticals's product category is Pharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325412 and its SIC code is 2834.